Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isosafrole is a small molecule phenylpropene and a structural analog of the antiepileptic drug stiripentol. Research published in *Science* by investigators at Okayama University identified isosafrole as a potent inhibitor of lactate dehydrogenase (LDH), an enzyme involved in the astrocyte-to-neuron lactate shuttle. By blocking LDH, isosafrole restricts the metabolic fuel available to neurons, thereby suppressing the hyperexcitability and excessive firing that characterize epileptic seizures. This mechanism effectively mimics the therapeutic metabolic shift induced by a ketogenic diet. In preclinical mouse models, isosafrole demonstrated superior anticonvulsant activity compared to stiripentol, suggesting its potential as a lead compound for a new class of antiepileptic therapies targeting brain energy metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isosafrole.